Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), a biopharmaceutical company, has announced the appointment of Enclave Capital and Peak Asset Management to initiate fundraising for the development of their patented pharmaceutical candidate, Conjugated Psilocin™. This move follows the company's recent establishment of Alera Pharma, Inc. as an operating entity for drug development.
Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences, emphasized the significance of this appointment in advancing their development plans, particularly in light of the recently issued new chemical entity patent for Conjugated Psilocin™. The company aims to progress this drug candidate through the US FDA NDA development process efficiently, focusing on treating diseases with significant unmet medical needs.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), una società biofarmaceutica, ha annunciato la nomina di Enclave Capital e Peak Asset Management per avviare la raccolta fondi per lo sviluppo del loro candidato farmaceutico brevettato, Conjugated Psilocin™. Questa mossa segue la recente istituzione da parte dell'azienda di Alera Pharma, Inc. come entità operativa per lo sviluppo di farmaci.
Il Dr. Fred Sancilio, Presidente e CEO di Lobe Sciences, ha sottolineato l'importanza di questa nomina per far progredire i loro piani di sviluppo, in particolare alla luce del recente rilascio del brevetto per nuova entità chimica per il Conjugated Psilocin™. L'azienda mira a portare avanti questo candidato farmaceutico attraverso il processo di sviluppo NDA della FDA degli Stati Uniti in modo efficiente, concentrandosi sul trattamento di malattie con bisogni medici non soddisfatti significativi.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), una compañía biofarmacéutica, ha anunciado el nombramiento de Enclave Capital y Peak Asset Management para iniciar la recaudación de fondos para el desarrollo de su candidato farmacéutico patentado, Conjugated Psilocin™. Este movimiento sigue al reciente establecimiento de Alera Pharma, Inc. como entidad operativa para el desarrollo de medicamentos.
El Dr. Fred Sancilio, Presidente y CEO de Lobe Sciences, enfatizó la importancia de este nombramiento para avanzar en sus planes de desarrollo, especialmente a la luz de la reciente emisión de la patente de nueva entidad química para Conjugated Psilocin™. La compañía busca avanzar este candidato a medicamento a través del proceso de desarrollo NDA de la FDA de EE. UU. de manera eficiente, enfocándose en el tratamiento de enfermedades con necesidades médicas significativas no satisfechas.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), 생물 의약품 회사가 Enclave Capital과 Peak Asset Management를 임명하여 그들의 특허 의약품 후보자인 Conjugated Psilocin™의 개발을 위한 자금 조달을 시작했다고 발표했습니다. 이 움직임은 회사가 의약품 개발을 위한 운영 단체로 Alera Pharma, Inc.를 최근에 설립한 데 따른 것입니다.
Lobe Sciences의 회장 겸 CEO인 Fred Sancilio 박사는 이 임명의 의미가 특히 Conjugated Psilocin™에 대한 새로운 화학 물질 특허의 최근 발급을 고려할 때 개발 계획을 추진하는 데 중요하다고 강조했습니다. 회사는 미국 FDA의 NDA 개발 과정을 통해 이 의약품 후보를 효율적으로 진행하고, 중대한 unmet medical needs가 있는 질병 치료에 집중할 계획입니다.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), une société bio-pharmaceutique, a annoncé la nomination de Enclave Capital et Peak Asset Management pour initier la collecte de fonds pour le développement de leur candidat pharmaceutique breveté, Conjugated Psilocin™. Ce mouvement fait suite à la récente création de Alera Pharma, Inc. en tant qu'entité opérationnelle pour le développement de médicaments.
Le Dr Fred Sancilio, président et PDG de Lobe Sciences, a souligné l'importance de cette nomination dans l'avancement de leurs plans de développement, en particulier à la lumière du récent brevet pour une nouvelle entité chimique pour le Conjugated Psilocin™. L'entreprise vise à faire progresser ce candidat médicamenteux de manière efficace à travers le processus de développement NDA de la FDA américaine, en se concentrant sur le traitement des maladies ayant des besoins médicaux non satisfaits significatifs.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF), ein biopharmazeutisches Unternehmen, hat die Ernennung von Enclave Capital und Peak Asset Management bekannt gegeben, um die Mittelbeschaffung für die Entwicklung ihres patentierten Arzneimittelkandidaten, Conjugated Psilocin™, zu initiieren. Dieser Schritt folgt der kürzlichen Gründung von Alera Pharma, Inc. als operative Einheit für die Arzneimittelentwicklung.
Dr. Fred Sancilio, Vorsitzender und CEO von Lobe Sciences, betonte die Bedeutung dieser Ernennung für den Fortschritt ihrer Entwicklungspläne, insbesondere im Hinblick auf das kürzlich erteilte Patent für eine neue chemische Substanz für Conjugated Psilocin™. Das Unternehmen zielt darauf ab, diesen Arzneimittelkandidaten effizient durch den US-FDA-NDA-Entwicklungsprozess voranzubringen, mit einem Schwerpunkt auf der Behandlung von Krankheiten mit erheblichen ungedeckten medizinischen Bedürfnissen.
- Appointment of Enclave Capital and Peak Asset Management to raise funds for clinical trials
- Recent issuance of a new chemical entity patent for Conjugated Psilocin™
- Creation of Alera Pharma, Inc. as an operating company for drug development
- None.
Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences explained “With the recent issuance of our new chemical entity patent on Conjugated Psilocin™, we are preparing to move this drug candidate forward through the US FDA NDA development process as quickly and efficiently as possible. The appointment of Enclave and Peak Asset Management is an important step to being able to advance our development plans”.
About Lobe Sciences, Ltd. - Lobe Sciences, Ltd. is a commercial stage biotechnology company focused on developing transformative therapies for unmet medical needs. Through its subsidiaries, Alera Pharma, Inc. and Altemia, Inc., Lobe Sciences is developing patented drug candidates to treat chronic cluster headache (Alera) and innovative medical foods to address deficiencies commonly seen in sickle cell disease (Altemia). Lobe provides common services to its subsidiaries including accounting, finance and general administrative services.
About Alera Pharma, Inc. - Alera Pharma, Inc. is a private subsidiary of Lobe Sciences, Ltd., dedicated to the development and commercialization of innovative pharmaceutical products. With a focus on addressing unmet medical needs, Alera Pharma is committed to improving patient outcomes in a variety of neurological disorders through cutting-edge research and development.
About Enclave Capital LLC - Enclave Capital LLC is as investment banking firm specializing in the healthcare and life sciences industries. With a proven track record of successful fundraising and strategic advisory services, Enclave Capital is dedicated to helping companies achieve their financial and strategic goals.
About Peak Asset Management - Peak Asset Management is a boutique investment management firm, headquartered in
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Cautionary Statement Regarding "Forward-Looking" Information
This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the Company’s intention to raise funds for clinical trials, the innovativeness of Conjugated PsilocinTM , the anticipated focus and timing or efficiency of the Company’s research and development activities; the FDA NDA process, or the potential ability to raise funds for clinical development are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur.
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company’s planned activities will be able to create shareholder value and address serious unmet medical needs; the Company will continue to pursue its planned research and development activities, that the company will be able to raise funds among others. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company’s planned activities will be unable to create shareholder value or address the targeted unmet medical needs; the Company is unable to obtain the desired results from its current research and development activities; and the Company is unable to raise funds or to do so on the timelines anticipated.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241016059997/en/
Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd.
Investor and Media
Info@Lobesciences.com
www.lobesciences.com
Source: Lobe Sciences, Ltd.
FAQ
What is the purpose of Lobe Sciences' (LOBEF) appointment of Enclave Capital and Peak Asset Management?
What recent milestone has Lobe Sciences (LOBEF) achieved for their Conjugated Psilocin™ drug candidate?
What is Alera Pharma, Inc.'s role in Lobe Sciences' (LOBEF) drug development process?
What is Lobe Sciences' (LOBEF) plan for their Conjugated Psilocin™ drug candidate?
